Noncoding RNA Gene Linked to Malignant Melanoma
By LabMedica International staff writers Posted on 05 Apr 2016 |

Image: Histopathology of a skin section from a patient with superficial spreading malignant melanoma (Photo courtesy of Profs. Leszek Wozniak and Krzysztof W. Zielinski).
While a large share of the human genome has long been considered “junk DNA” because it does not contribute to protein coding, recent insights indicate that it does produce many noncoding ribonucleic acids (RNAs) that play important roles in essential biological processes and diseases.
A remarkable link has been found between malignant melanoma and a noncoding RNA gene called SAMMSON. The SAMMSON gene is expressed in human malignant melanoma and, strikingly, the growth of aggressive skin cancer is highly dependent on this gene. The conclusions could pave the way for improved diagnostic tools and skin cancer treatment.
A European group of scientists led by those at the VIB, the Flanders Institute for Biotechnology (Leuven, Belgium) have shown that show that the recently annotated long noncoding RNA (lncRNA) gene SAMMSON is consistently co-gained with Microphthalmia-Associated Transcription Factor (MITF) gene. Their results indicate that silencing of the lineage addiction oncogene SAMMSON disrupts vital mitochondrial functions in a cancer-cell-specific manner; this silencing is therefore expected to deliver highly effective and tissue-restricted anti-melanoma therapeutic responses.
The scientists discovered a remarkable dependency of melanoma cells on SAMMSON expression. When reducing the presence of SAMMSON in melanoma cultures, cancer cells rapidly and massively die off, irrespective of the type of melanoma. This led to the key conclusion of a “SAMMSON addiction.” As the SAMSSON gene is not expressed in benign melanoma, its occurrence could be a key factor in developing new diagnostic tools that may dramatically improve melanoma prognosis.
Pieter Mestdagh, PhD, from Ghent University (Belgium) and a senior coauthor of the study, said, “Our study showed that the long noncoding RNA gene SAMMSON is specifically expressed in human melanomas and duplicated or amplified in about 10% of the cases. In addition, SAMMSON was nowhere to be found in melanocytes, the normal melanin-producing cells, nor in any other normal adult tissue. This unique expression profile of SAMMSON led us to hypothesize that this gene might play an important role in the etiology of melanoma.” The study was published on March 23, 2016, in the journal Nature.
Related Links:
VIB the Flanders Institute for Biotechnology
Ghent University
A remarkable link has been found between malignant melanoma and a noncoding RNA gene called SAMMSON. The SAMMSON gene is expressed in human malignant melanoma and, strikingly, the growth of aggressive skin cancer is highly dependent on this gene. The conclusions could pave the way for improved diagnostic tools and skin cancer treatment.
A European group of scientists led by those at the VIB, the Flanders Institute for Biotechnology (Leuven, Belgium) have shown that show that the recently annotated long noncoding RNA (lncRNA) gene SAMMSON is consistently co-gained with Microphthalmia-Associated Transcription Factor (MITF) gene. Their results indicate that silencing of the lineage addiction oncogene SAMMSON disrupts vital mitochondrial functions in a cancer-cell-specific manner; this silencing is therefore expected to deliver highly effective and tissue-restricted anti-melanoma therapeutic responses.
The scientists discovered a remarkable dependency of melanoma cells on SAMMSON expression. When reducing the presence of SAMMSON in melanoma cultures, cancer cells rapidly and massively die off, irrespective of the type of melanoma. This led to the key conclusion of a “SAMMSON addiction.” As the SAMSSON gene is not expressed in benign melanoma, its occurrence could be a key factor in developing new diagnostic tools that may dramatically improve melanoma prognosis.
Pieter Mestdagh, PhD, from Ghent University (Belgium) and a senior coauthor of the study, said, “Our study showed that the long noncoding RNA gene SAMMSON is specifically expressed in human melanomas and duplicated or amplified in about 10% of the cases. In addition, SAMMSON was nowhere to be found in melanocytes, the normal melanin-producing cells, nor in any other normal adult tissue. This unique expression profile of SAMMSON led us to hypothesize that this gene might play an important role in the etiology of melanoma.” The study was published on March 23, 2016, in the journal Nature.
Related Links:
VIB the Flanders Institute for Biotechnology
Ghent University
Latest Molecular Diagnostics News
- Blood-Based Biomarkers Could Detect Alzheimer's as Early as Middle Age
- RNA Screening Test Could Detect Colon Polyps Before They Become Cancerous
- New RT-LAMP Assay Offers Affordable and Reliable Pathogen Detection for Resource-Limited Settings
- New Biomarker Panel to Enable Early Detection of Pancreatic Cancer
- Ultrarapid Whole Genome Sequencing for Neonatal and Pediatric Patients Delivers Results In 48 Hours
- AI-Enabled Blood Test Demonstrates Diagnostic, Prognostic and Predictive Utility Across Cancer Continuum
- DNA Methylation Signatures of Aging Could Help Assess Mortality Risk
- Molecular Diagnostics System Provides Lab-Quality Results at POC
- Cellular Signature Identifies Patients with Treatment Resistant Prostate Tumors
- MCED Could Be Valuable Supplement to Traditional Cancer Screening Approaches
- Newly-Cleared Technology a Game Changer for Diagnosis of Lyme Disease
- Innovative Liquid Biopsy Test Uses RNA to Detect Early-Stage Cancer
- Rapid Tests for Chagas Disease Improves Diagnostic Access
- Simple Blood Test to Predict Alzheimer’s Clinical Progression in Earliest Stages
- Saliva Test Could Identify People Genetically Susceptible to Type 2 Diabetes
- Pioneering Analyzer with Advanced Biochip Technology Sets New Standard in Lab Diagnostics
Channels
Clinical Chemistry
view channel
New Clinical Chemistry Analyzer Designed to Meet Growing Demands of Modern Labs
A new clinical chemistry analyzer is designed to provide outstanding performance and maximum efficiency, without compromising affordability, to meet the growing demands of modern laboratories.... Read more
New Reference Measurement Procedure Standardizes Nucleic Acid Amplification Test Results
Nucleic acid amplification tests (NAATs) play a key role in diagnosing a wide range of infectious diseases. These tests are generally known for their high sensitivity and specificity, and they can be developed... Read moreHematology
view channel
Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results
Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more
First Point-of-Care Heparin Monitoring Test Provides Results in Under 15 Minutes
Heparin dosing requires careful management to avoid both bleeding and clotting complications. In high-risk situations like extracorporeal membrane oxygenation (ECMO), mortality rates can reach about 50%,... Read moreImmunology
view channel
Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer
Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more
Groundbreaking Lateral Flow Test Quantifies Nucleosomes in Whole Venous Blood in Minutes
Diagnosing immune disruptions quickly and accurately is crucial in conditions such as sepsis, where timely intervention is critical for patient survival. Traditional testing methods can be slow, expensive,... Read moreMicrobiology
view channel
Viral Load Tests Can Help Predict Mpox Severity
Mpox is a viral infection that causes flu-like symptoms and a characteristic rash, which evolves significantly over time and varies between patients. The disease spreads mainly through direct contact with... Read more
Gut Microbiota Analysis Enables Early and Non-Invasive Detection of Gestational Diabetes
Gestational diabetes mellitus is a common metabolic disorder marked by abnormal glucose metabolism during pregnancy, typically emerging in the mid to late stages. It significantly heightens the risk of... Read morePathology
view channel
Novel Method Tracks Cancer Treatment in Cells Without Dyes or Labels
Multiple myeloma is a blood cancer that affects plasma cells in the bone marrow, leading to abnormal protein production, weakened immunity, and organ damage. Traditional methods for evaluating myeloma... Read more
New AI-Based Method Effectively Identifies Disease Phenotypes Using Light-Based Imaging
Precision medicine, where treatment strategies are tailored to a patient's unique disease characteristics, holds great promise for cancer therapy. However, identifying disease phenotypes, which are critical... Read more
AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care
Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read moreTechnology
view channel
Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation
Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Ultra-Sensitive Biosensor Based on Light and AI Enables Early Cancer Diagnosis
Cancer diagnosis is often delayed due to the difficulty in detecting early-stage cancer markers. In particular, the concentration of methylated DNA in the bloodstream during the early stages of cancer... Read moreIndustry
view channel
BD Biosciences & Diagnostic Solutions to Merge with Waters
BD (Becton, Dickinson and Company, Franklin Lakes, NJ, USA) and Waters Corporation (Milford, MA, USA) have entered into a definitive agreement to combine BD's Biosciences & Diagnostic Solutions... Read more